|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
KR20080026654A
(ko)
|
2005-07-14 |
2008-03-25 |
아스텔라스세이야쿠 가부시키가이샤 |
헤테로시클릭 야누스 키나제 3 억제제
|
|
TWI630207B
(zh)
|
2005-12-13 |
2018-07-21 |
英塞特控股公司 |
作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
|
|
US8084646B2
(en)
|
2006-11-02 |
2011-12-27 |
Shionogi & Co., Ltd. |
Process for production of hydroxyadamantaneamine
|
|
WO2008084861A1
(ja)
*
|
2007-01-12 |
2008-07-17 |
Astellas Pharma Inc. |
縮合ピリジン化合物
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
WO2009007839A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Pfizer Inc. |
Pharmaceutical compositions and methods of treating dry eye disorders
|
|
EP2074120B1
(en)
*
|
2007-10-25 |
2010-03-03 |
Exelixis, Inc. |
Tropane compounds
|
|
HUE028347T2
(en)
|
2008-06-10 |
2016-12-28 |
Abbvie Inc |
Tricyclic compounds
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
WO2010058846A1
(ja)
*
|
2008-11-21 |
2010-05-27 |
アステラス製薬株式会社 |
４，６-ジアミノニコチンアミド化合物
|
|
AU2009320683B2
(en)
*
|
2008-11-28 |
2012-07-19 |
Kowa Company, Ltd. |
Pyridine-3-carboxyamide derivative
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
EP3643312A1
(en)
|
2009-05-22 |
2020-04-29 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
CN102459267B
(zh)
|
2009-06-08 |
2014-11-26 |
武田药品工业株式会社 |
用作jak抑制剂的二氢吡咯并萘啶酮化合物
|
|
EP2451813B1
(en)
|
2009-07-08 |
2014-10-01 |
Leo Pharma A/S |
Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
|
|
FR2948370B1
(fr)
|
2009-07-27 |
2013-04-05 |
Sanofi Aventis |
Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
|
|
FR2948369B1
(fr)
|
2009-07-27 |
2013-04-12 |
Sanofi Aventis |
Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
EA201290147A1
(ru)
|
2009-10-15 |
2012-11-30 |
Пфайзер Инк. |
Пирроло[2,3-d]пиримидиновые соединения
|
|
ME02800B
(me)
*
|
2009-12-01 |
2018-01-20 |
Abbvie Inc |
Nova triciklična jedinjenja
|
|
KR20120102724A
(ko)
*
|
2009-12-01 |
2012-09-18 |
아보트 러보러터리즈 |
신규한 트리사이클릭 화합물
|
|
WO2011075334A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
US8461328B2
(en)
|
2010-01-12 |
2013-06-11 |
Genentech, Inc. |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
EP3050882B1
(en)
|
2010-03-10 |
2018-01-31 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
US8518945B2
(en)
|
2010-03-22 |
2013-08-27 |
Hoffmann-La Roche Inc. |
Pyrrolopyrazine kinase inhibitors
|
|
US8481541B2
(en)
|
2010-03-22 |
2013-07-09 |
Hoffmann-La Roche Inc. |
Pyrrolopyrazine kinase inhibitors
|
|
KR20130083387A
(ko)
|
2010-05-20 |
2013-07-22 |
에프. 호프만-라 로슈 아게 |
Syk 및 jak 억제제로서 피롤로피라진 유도체
|
|
SG10201503983QA
(en)
|
2010-05-21 |
2015-06-29 |
Incyte Corp |
Topical Formulation for a JAK Inhibitor
|
|
JP5888612B2
(ja)
*
|
2010-06-23 |
2016-03-22 |
アステラス製薬株式会社 |
縮合ピリジン化合物塩の結晶
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
CN103415515B
(zh)
|
2010-11-19 |
2015-08-26 |
因塞特公司 |
作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
RU2013136906A
(ru)
*
|
2011-01-07 |
2015-02-20 |
Лео Фарма А/С |
Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
EP2688890B1
(en)
|
2011-03-22 |
2017-08-30 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
PE20140832A1
(es)
|
2011-06-20 |
2014-07-14 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
PH12013502670A1
(en)
|
2011-08-12 |
2016-07-29 |
Nissan Chemical Ind Ltd |
Tricyclic heterocyclic compounds and jak inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
DK2796460T3
(en)
*
|
2011-12-21 |
2018-08-27 |
Jiangsu Hengrui Medicine Co |
SEXUAL PYRROL HETEROARYL RING DERIVATIVES, METHOD OF PREPARATION AND MEDICAL APPLICATIONS THEREOF
|
|
ES2567552T3
(es)
*
|
2012-01-30 |
2016-04-25 |
Cephalon, Inc. |
Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
|
|
UY34615A
(es)
*
|
2012-02-10 |
2013-09-30 |
Galapagos Nv |
Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
|
|
WO2013117649A1
(en)
*
|
2012-02-10 |
2013-08-15 |
Galapagos Nv |
Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
|
|
JP6123795B2
(ja)
*
|
2012-03-30 |
2017-05-10 |
アステラス製薬株式会社 |
放出制御医薬組成物
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
GB201211021D0
(en)
*
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
|
CA2884710A1
(en)
|
2012-09-12 |
2014-03-20 |
Rigel Pharmaceuticals, Inc. |
Treatment for vitiligo
|
|
EP2897962A1
(en)
|
2012-09-21 |
2015-07-29 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
PL2919766T3
(pl)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
|
|
TW201513861A
(zh)
*
|
2013-01-17 |
2015-04-16 |
Galapagos Nv |
用於治療退化性及發炎疾病之新穎化合物
|
|
JP6248948B2
(ja)
|
2013-02-08 |
2017-12-20 |
日産化学工業株式会社 |
３環性ピロロピリジン化合物及びｊａｋ阻害剤
|
|
CN105189509B
(zh)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
用于制备jak抑制剂的方法及中间体
|
|
WO2014146246A1
(en)
*
|
2013-03-19 |
2014-09-25 |
Merck Sharp & Dohme Corp. |
Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
|
|
WO2014157603A1
(ja)
|
2013-03-29 |
2014-10-02 |
アステラス製薬株式会社 |
経口投与用医薬組成物
|
|
SG10201912203XA
(en)
|
2013-08-07 |
2020-02-27 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
KR101548492B1
(ko)
|
2013-09-23 |
2015-09-01 |
건국대학교 산학협력단 |
야누스 키나아제 1 (Janus kinase 1)의 활성을 선택적으로 저해하는 4-아미노-7-아자인돌-5-카르복사마이드 유도체
|
|
WO2015083028A1
(en)
|
2013-12-05 |
2015-06-11 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
|
|
CA2945778A1
(en)
*
|
2014-04-22 |
2015-10-29 |
Arqule, Inc. |
Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
|
|
AU2015260349B2
(en)
|
2014-05-14 |
2019-02-21 |
Nissan Chemical Industries, Ltd. |
Tricyclic compound and JAK inhibitor
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
WO2016047678A1
(ja)
*
|
2014-09-25 |
2016-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
SG10201912699RA
(en)
*
|
2015-07-20 |
2020-02-27 |
Genzyme Corp |
Colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
KR20250010141A
(ko)
|
2015-10-16 |
2025-01-20 |
애브비 인코포레이티드 |
(3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10730871B2
(en)
*
|
2016-01-28 |
2020-08-04 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
CA3030283A1
(en)
|
2016-07-08 |
2018-01-11 |
Rigel Pharmaceuticals, Inc. |
Tyrosine kinase inhibitors
|
|
JOP20190144A1
(ar)
|
2016-12-16 |
2019-06-16 |
Janssen Pharmaceutica Nv |
إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
|
|
AU2017377069B2
(en)
|
2016-12-16 |
2020-07-23 |
Janssen Pharmaceutica Nv |
Small molecule inhibitors of the JAK family of kinases
|
|
JP2018104412A
(ja)
*
|
2016-12-22 |
2018-07-05 |
参天製薬株式会社 |
眼疾患の治療及び／又は予防剤
|
|
CR20190310A
(es)
|
2016-12-29 |
2019-08-21 |
Hoffmann La Roche |
Compuestos de pirazolopirimidina y métodos de uso de los mismos
|
|
DK3604304T3
(da)
*
|
2017-03-23 |
2022-10-31 |
Daegu Gyeongbuk Medical Innovation Found |
Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme
|
|
WO2019057103A1
(zh)
*
|
2017-09-21 |
2019-03-28 |
上海华汇拓医药科技有限公司 |
Jak激酶抑制剂及其制备方法和在医药领域的应用
|
|
GB201717260D0
(en)
*
|
2017-10-20 |
2017-12-06 |
Galapagos Nv |
Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
|
|
US10800775B2
(en)
|
2017-11-03 |
2020-10-13 |
Aclaris Therapeutics, Inc. |
Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
|
|
BR112020008850A2
(pt)
*
|
2017-11-03 |
2020-10-20 |
Aclaris Therapeutics, Inc. |
composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
EP3746429B1
(en)
|
2018-01-30 |
2022-03-09 |
Incyte Corporation |
Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
PT3773593T
(pt)
|
2018-03-30 |
2024-06-25 |
Incyte Corp |
Tratamento da hidradenite supurativa com inibidores de jak
|
|
TW202016110A
(zh)
|
2018-06-15 |
2020-05-01 |
比利時商健生藥品公司 |
Ｊａｋ激酶家族之小分子抑制劑
|
|
US12060350B2
(en)
|
2018-07-02 |
2024-08-13 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods of use thereof
|
|
CN112823005B
(zh)
|
2018-08-10 |
2024-08-20 |
阿克拉瑞斯治疗股份有限公司 |
吡咯并嘧啶itk抑制剂
|
|
WO2020081689A1
(en)
*
|
2018-10-16 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Azaindole inhibitors of wild-type and mutant forms of lrrk2
|
|
EP3915985A4
(en)
|
2019-01-18 |
2022-09-28 |
Voronoi Co., Ltd. |
PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
|
|
EP3939979A4
(en)
*
|
2019-03-14 |
2022-04-06 |
Shanghai Synergy Pharmaceutical Sciences Co., Ltd |
Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
|
|
KR20220004726A
(ko)
|
2019-05-02 |
2022-01-11 |
어클라리스 쎄라퓨틱스, 인코포레이티드 |
Jak 억제제로서의 치환된 피롤로피리딘
|
|
KR102286372B1
(ko)
*
|
2019-05-27 |
2021-08-05 |
주식회사한국파마 |
Jak 저해제 화합물, 및 이를 포함하는 의약 조성물
|
|
CN112174951A
(zh)
*
|
2019-07-02 |
2021-01-05 |
深圳美莹基因科技有限公司 |
作为詹纳斯激酶1选择抑制剂的吡咯并[2，3-b]吡啶衍生物
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11753413B2
(en)
|
2020-06-19 |
2023-09-12 |
Incyte Corporation |
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
|
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
|
KR20230057341A
(ko)
*
|
2020-07-02 |
2023-04-28 |
인사이트 코포레이션 |
Jak2 v617f 억제제로서 삼환계 우레아 화합물
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
WO2022046989A1
(en)
|
2020-08-27 |
2022-03-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
KR102551758B1
(ko)
*
|
2020-11-30 |
2023-07-05 |
주식회사한국파마 |
신규한 jak 특이 저해제 화합물, 및 이의 제조방법
|
|
KR20220081631A
(ko)
|
2020-12-09 |
2022-06-16 |
보로노이 주식회사 |
염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
|
|
WO2022140231A1
(en)
|
2020-12-21 |
2022-06-30 |
Incyte Corporation |
Deazaguaine compounds as jak2 v617f inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
AU2022233254A1
(en)
|
2021-03-11 |
2023-10-26 |
Janssen Pharmaceutica Nv |
Lorpucitinib for use in the treatment of jak mediated disorders
|
|
PE20251706A1
(es)
|
2022-03-17 |
2025-07-02 |
Incyte Corp |
Compuestos de urea triciclica como inhibidores de v617f de jak2
|
|
WO2023208174A1
(zh)
*
|
2022-04-28 |
2023-11-02 |
杭州普济远成生物医药科技有限公司 |
去泛素化酶抑制剂及其应用
|
|
CN116283963A
(zh)
*
|
2022-12-05 |
2023-06-23 |
西安美莹基因科技有限公司 |
一种高效詹纳斯激酶1选择性抑制剂
|